Evidence map›Paper›PMID 32778102›Full record

ArticleBMC health services research2020

A cluster randomized controlled trial for the Evaluation of routinely Measured PATient reported outcomes in HemodialYsis care (EMPATHY): a study protocol.

Jeffrey A Johnson, Fatima Al Sayah, Robert Buzinski, Bonnie Corradetti, Sara N Davison, Meghan J Elliott, Scott Klarenbach, Braden Manns, Kara Schick-Makaroff, Hilary Short and 2 more

Registry-linked trialAbstract readClinical Trial Protocol
In one paragraph

Article in BMC health services research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03535922 (Evaluation of Routinely Measured PATtient Reported Outcomes in HemodialYsis Care), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03535922 nacompletednot on this map

Evaluation of Routinely Measured PATtient Reported Outcomes in HemodialYsis Care (EMPATHY) Trial: A Cluster Randomized Controlled Trial

TypeinterventionalSponsorUniversity of AlbertaRan2018 to 2025Enrolled3,977ConditionsChronic Kidney Disease Requiring Chronic DialysisArmsPROMs Assessment
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Mapping the Edmonton Symptom Assessment System-Revised: Renal to the EQ-5D-5L in patients with chronic kidney disease.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022
    Trial
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Advances in Human-Centered Care to Address Contemporary Unmet Needs in Chronic Dialysis.International journal of nephrology and renovascular disease · 2024
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Screening for symptoms of anxiety and depression in patients treated with renal replacement therapy: utility of the Edmonton Symptom Assessment System-Revised.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jeffrey A Johnson2-040 Li Ka Shing Centre for Health Research Innovation, School of Public Health, University of Alberta, Edmonton, AB, T6G 2E1, Canada. jeff.johnson@ualberta.ca.ORCID http://orcid.org/0000-0001-8290-2857
Fatima Al Sayah2-040 Li Ka Shing Centre for Health Research Innovation, School of Public Health, University of Alberta, Edmonton, AB, T6G 2E1, Canada.
Robert BuzinskiPatient Partner, Medicine Hat, Alberta, Canada.
Bonnie CorradettiPatient Partner, Medicine Hat, Alberta, Canada.
Sara N Davison11-113L Clinical Sciences Building, Division of Nephrology and Immunology, Department of Medicine, University of Alberta, Edmonton, AB, T6G 2G3, Canada.
Meghan J ElliottFoothills Medical Centre, 1403 - 29th Street NW, Calgary, AB, T2N 2T9, Canada.
Scott Klarenbach11-107 Clinical Sciences Building, Division of Nephrology and Immunology, Department of Medicine, University of Alberta, Edmonton, AB, T6G 2G3, Canada.
Braden MannsFoothills Medical Centre, 1403 - 29th Street NW, Calgary, AB, T2N 2T9, Canada.
Kara Schick-Makaroff5-295 Edmonton Clinic Health Academy, Faculty of Nursing, University of Alberta, Edmonton, AB, T6G 1C9, Canada.
Hilary Short2-040 Li Ka Shing Centre for Health Research Innovation, School of Public Health, University of Alberta, Edmonton, AB, T6G 2E1, Canada.
Chandra ThomasFoothills Medical Centre, 1403 - 29th Street NW, Calgary, AB, T2N 2T9, Canada.
Michael WalshDivision of Nephrology, Department of Medicine, McMaster University, Marion Wing, Level 3, St. Joseph's Healthcare, 50 Charlton Ave. E, Hamilton, ON, L8N 4A6, Canada.

Funding

Canadian Institutes of Health Research (CIHR) SCA-145103
6 · The paper itself

Abstract

backgroundKidney failure requiring dialysis is associated with poor health outcomes and health-related quality of life (HRQL). Patient-reported outcome measures (PROMs) capture symptom burden, level of functioning and other outcomes from a patient perspective, and can support clinicians to monitor disease progression, address symptoms, and facilitate patient-centered care. While evidence suggests the use of PROMs in clinical practice can lead to improved patient experience in some settings, the impact on patients' health outcomes and experiences is not fully understood, and their cost-effectiveness in clinical settings is unknown. This study aims to fill these gaps by evaluating the effectiveness and cost-effectiveness of routinely measuring PROMs on patient-reported experience, clinical outcomes, HRQL, and healthcare utilization.

methodsThe EMPATHY trial is a pragmatic multi-centre cluster randomized controlled trial that will implement and evaluate the use of disease-specific and generic PROMs in three kidney care programs in Canada. In-centre hemodialysis units will be randomized into four groups, whereby patients: 1) complete a disease-specific PROM; 2) complete a generic PROM; 3) complete both types of PROMs; 4) receive usual care and do not complete any PROMs. While clinical care pathways are available to all hemodialysis units in the study, for the three active intervention groups, the results of the PROMs will be linked to treatment aids for clinicians and patients. The primary outcome of this study is patient-provider communication, assessed by the Communication Assessment Tool (CAT). Secondary outcomes include patient management and symptoms, use of healthcare services, and the costs of implementing this intervention will also be estimated. The present protocol fulfilled the Standard Protocol Items: Recommendations for Intervention Trials (SPIRIT) checklist. DISCUSSION: While using PROMs in clinical practice is supported by theory and rationale, and may engage patients and enhance their role in decisions regarding their care and outcomes, the best approach of their use is still uncertain. It is important to rigorously evaluate such interventions and investments to ensure they provide value for patients and health systems.

trial registrationProtocol version (1.0) and trial registration data are available on www.clinicaltrials.gov , identifier: NCT03535922 , registered May 24, 2018.

Indexed as

Patient Reported Outcome MeasuresRenal DialysisCanadaCost-Benefit AnalysisHumansMulticenter Studies as TopicPatient Acceptance of Health CarePragmatic Clinical Trials as TopicQuality of LifeRandomized Controlled Trials as TopicResearch DesignTreatment OutcomeControlled trialHemodialysisKidney failurePatient-reported outcome measuresQuality improvementSymptom burden

Identifiers

PMID32778102
PMCPMC7418420

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.